Search research articles
Contact Us
Filters
Showing results (81-90 of 102) with videos related to
Page
of 11
Sort By:
Parasitology
|
April 2, 2002
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection
J A Simpson, L Aarons, W E Collins, et al.
British Journal of Clinical Pharmacology
|
November 1, 1990
Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin
S Toon, B L Holt, F G Mullins, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
April 12, 2001
Role of modelling and simulation in Phase I drug development
L Aarons, M O Karlsson, F Mentré, et al.
British Journal of Clinical Pharmacology
|
March 1, 1983
Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis--rate of response and lack of time dependency of plasma pharmacokinetics
L Aarons, D M Grennan, C Rajapakse, et al.
Clinical Pharmacology and Therapeutics
|
March 7, 2014
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach
N Tsamandouras, G Dickinson, Y Guo, et al.
Clinical Pharmacokinetics
|
February 1, 1996
The use of population pharmacokinetics in drug development
S Vozeh, J L Steimer, M Rowland, et al.
Clinical Pharmacology and Therapeutics
|
July 3, 1999
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships
S K Gupta, G Sathyan, E A Lindemulder, et al.
European Journal of Clinical Pharmacology
|
January 1, 1993
New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research
L P Balant, M Rowland, L Aarons, et al.
Antimicrobial Agents and Chemotherapy
|
November 18, 2000
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance
J A Simpson, E R Watkins, R N Price, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 20, 2001
An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine
N D Evans, K R Godfrey, M J Chapman, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 102) with videos related to
Sort By:
Page
of 11
Parasitology
|
April 2, 2002
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection
J A Simpson, L Aarons, W E Collins, et al.
British Journal of Clinical Pharmacology
|
November 1, 1990
Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin
S Toon, B L Holt, F G Mullins, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
April 12, 2001
Role of modelling and simulation in Phase I drug development
L Aarons, M O Karlsson, F Mentré, et al.
British Journal of Clinical Pharmacology
|
March 1, 1983
Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis--rate of response and lack of time dependency of plasma pharmacokinetics
L Aarons, D M Grennan, C Rajapakse, et al.
Clinical Pharmacology and Therapeutics
|
March 7, 2014
Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach
N Tsamandouras, G Dickinson, Y Guo, et al.
Clinical Pharmacokinetics
|
February 1, 1996
The use of population pharmacokinetics in drug development
S Vozeh, J L Steimer, M Rowland, et al.
Clinical Pharmacology and Therapeutics
|
July 3, 1999
Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships
S K Gupta, G Sathyan, E A Lindemulder, et al.
European Journal of Clinical Pharmacology
|
January 1, 1993
New strategies in drug development and clinical evaluation: the population approach. Commentary on an action for co-operative research
L P Balant, M Rowland, L Aarons, et al.
Antimicrobial Agents and Chemotherapy
|
November 18, 2000
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance
J A Simpson, E R Watkins, R N Price, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 20, 2001
An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine
N D Evans, K R Godfrey, M J Chapman, et al.
Page
of 11